The German Institute for International and Security Affairs (SWP) has published an article discussing interregional opportunities for pharmaceutical supply chains. It highlights data concerning Latin America, particularly focusing on Mercosur’s relations with the European Union in the pharmaceutical sector.

In its comprehensive analysis, which you can read in full here, they reference data from AMI:

A similarly strong market can be found in Argentina, even considering the difficult state of the nation’s economy, with several domestic companies producing specialised APIs as well as biosimilars. Although Brazil and Argentina are generally considered the most important sites for pharmaceutical innovation and production, the EU should also focus on Uruguay and Paraguay, as both countries hold considerable capacities and currently mostly supply domestic markets.